These therapies are RNA-based (not miRNA-based); they do not knockdown or overexpress miRNAs but target oncogenes such as Bcl-2 (NCT00285103) in CLL, STAT3 (NCT01563302) in DLBCL and lymphoma, and MYC (NCT02314052) in HCC. This evidence concerns the gene STAT3 and diffuse large B-cell lymphoma.